The TGA recommends that semaglutide supplies be reserved for those who have no other treatment options available to them
Mentlein, R
doi: 10.3389/fimmu.2026.1797949 Received 28 January 2026 Revised 30 March 2026 Accepted 08 April 2026 Published 30 April 2026 Volume 17 - 2026 Edited by Pamela Valva, General Hospital of Children Ricardo Gutierrez, Argentina Reviewed by Pedro Miguel Rodrigues, Biodonostia Health Research Institute (IIS Biodonostia), Spain Felix Wensveen, University of Rijeka, Croatia Updates Copyright 2026 Gonzlez-Serrano, Onoiu, Jimnez-Franco, Cambra-Corts, Camps and Joven
Eligibility criteria The inclusion criteria were as follows: 1) RCTs that have included participants with obesity defined as BMI of 30 kg/m 2 or higher, or 27 kg/m 2 or higher if accompanied by one or more comorbidities, 2) evaluated the safety and efficacy of semaglutide or tirzepatide for weight reduction in the intervention arm, 3) has a control group for comparison, 4) reported at least one of the following safety outcomes: GI adverse events, hepatic adverse events, new cases of pancreatitis, gallbladder and biliary disorders
Step 3: Preparation (5-10 minutes) A sterile IV line is inserted in your arm following strict medical protocols
It does, however, take time, hard work, and perseverance
